Candid Summaries on CBD Studies

Osteoarthritis: Safety and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs

KEY TAKEAWAYS:

  • During CBD treatment, dogs’ pain decreased with pain scores dropping from 21 to 14 (0-50 scale)
  • Use of CBD oil result in a 12% increase in dogs’ activity 
  • No side effects were reported by owners.  
  • These clinic results suggest that the use of 2 mg/kg CBD twice a day can increase the comfort and activity of dogs suffering from osteoarthritis 
Continue reading
Osteoarthritis: Daily use of CBD for the Treatment of Canine Osteoarthritis Pain

KEY TAKEAWAYS:

  • 50 mg/day of CBD or 20 mg/day of liposomal CBD significantly reduced pain in dogs suffering from osteoarthritis
  • Packaging CBD within a liposome (delivery method) forms liposomal CBD and improves CBD’s bioavailability and absorption 
  • Movement indexes (standing, walking and running) were all improved after administration of both 50mg/day CBD and 20 mg/day liposomal CBD
  • Dog’s quality of life increased after CBD treatment
  • The study supports the safety and therapeutic potential of CBD for relieving arthritic pain and improving dog’s activity levels
  • No detrimental impact of CBD administration was reported
Continue reading
Cancer: Efficacy, Safety & Tolerability of Cannabinoids in Patients with Intractable Cancer-Related Pain

KEY TAKEAWAYS:

  • 43% of participants experienced a  ≥30% reduction in cancer-related pain intensity after cannabinoid treatment 
  • 20% of cats and 25% of dogs will be diagnosed with cancer in their lifetime
  • After 2 weeks of receiving CBD+THC in addition to all other treatments, there was a statistically significant reduction in pain severity when compared with placebo
  • The addition of CBD resulted in a increase of 20% in the response rate 
  • A greater proportion of patients in the cannabinoid treatment group reduced other pain medication doses whereas the highest proportion of increases in dose was in the placebo group
  • Administration of THC+CBD was well tolerated and no safety concerns were identified 
Continue reading
Pain: Non-Psychoactive Cannabidiol is an Orally Effective Therapeutic Agent in Chronic and Neurophatic Pain

KEY TAKEAWAYS:

  • CBD reversed hyperalgesia after 7 days of oral treatment in 2 models of persistent pain in rats
  • Repeated administration of CBD oil abolished/reduced the levels of molecules implicated in the pathogenesis of many inflammatory disorders and pain installation
  • The study put into evidence the anti-hyperalgesic potency of CBD, while being a non-toxic and non-psychotropic agent 
Continue reading
Arthritis: Topical CBD use Reduces Inflammation and Pain-Related Behaviours Linked to Arthritis

KEY TAKEAWAYS:

  • Topical CBD proved to be an effective symptomatic, anti-inflammatory and anti-hyperalgesic treatment in arthritis
  • The subjects didn’t suffer any alteration in their activity levels or motor abilities.
  • A dose of 6.2mg/day of CBD significantly reduced swelling and synovial thickness
  • Transdermal CBD use improved pain, reducing the median score from 4 to 1.5 (0-5 scale)
  • Only after 2 days of CBD treatment, there was a significant improvement of heat hypersensitivity, which persisted throughout the experiment
  • Pro-inflammatory activity dropped as low as non-pathological levels after using CBD
Continue reading